Category: Stock Market

Get the latest finance and stock market news. Updates on Wall Street, NASDAQ, crypto, IPOs, mutual funds, and investing tips.

TruAlt Bioenergy IPO GMP Today: Grey Market Premium, Subscription Status & Share Price Target 2025

Post author By John Martin
Post date September 29, 2025

TruAlt Bioenergy IPO GMP Today: Grey Market Premium, Subscription Status & Share Price Target 2025

TruAlt Bioenergy IPO GMP Today

The TruAlt Bioenergy IPO GMP today is ₹109, indicating strong grey market demand. With an issue price band of ₹472–₹496, this premium points to a listing around ₹605 per share—a gain of nearly 22% above the upper band.

Investors tracking TruAlt Bioenergy IPO GMP today live and TruAlt Bioenergy IPO GMP today price are finding consistent buzz, showing the IPO is expected to deliver healthy listing gains.

TruAlt Bioenergy IPO Details

IPO Open Date: September 25, 2025
IPO Close Date: September 29, 2025
IPO Size: ₹839.28 crore
- Fresh Issue: ₹750 crore
- Offer For Sale (OFS): ₹89.28 crore
Price Band: ₹472–₹496 per share
Lot Size: 30 shares (₹14,880 at upper band)
Basis of Allotment: September 30, 2025
Listing Date: October 3, 2025 (BSE & NSE)
Lead Manager: Dam Capital Advisors Ltd
Registrar: Bigshare Services Pvt. Ltd

The IPO already raised ₹251.78 crore from anchor investors on September 24, adding credibility to its market interest.

TruAlt Bioenergy IPO Subscription Status (Day 3)

As of September 29 (Day 3, 10:35 am):

Overall: 2.25× subscribed
Retail Investors: 1.64× subscribed
Non-Institutional Investors (NII): 5.48× subscribed
Qualified Institutional Buyers (QIBs): 0.90× subscribed

The strong subscription from retail and HNIs signals robust sentiment, even though QIB participation is still building.

TruAlt Bioenergy – Company Overview

TruAlt Bioenergy, headquartered in Bengaluru, is a leading biofuels and ethanol producer with an installed ethanol capacity of 2,000 KLPD.

TruAlt Bioenergy Core Businesses:

Ethanol & Biofuels: Focus on renewable and clean energy solutions.
Transformers: Produces power, inverter-duty, furnace, generator, and special-duty transformers.
Manufacturing: 4,400 transformers delivered (94,000 MVA capacity) across India.
Facilities: Five plants (4 operational) across Gujarat & Karnataka, including a new Vadodara unit.

TruAlt Bioenergy IPO Fund Utilisation:

₹150.68 crore for multi-feed stock operations
₹425 crore for working capital
Balance for general corporate purposes

TruAlt Bioenergy Share Price Target 2025

Brokerages remain optimistic about long-term prospects in bioenergy:

Listing Target (2025 short term): ₹605–₹620
Medium-Term Target 2025: ₹700–₹750
Drivers: Government ethanol blending policy, renewable energy growth, anchor investor confidence.

Reliance Securities notes the company’s strong portfolio and sector demand, while SBI Securities highlights a FY22–25 CAGR of 58% in Revenue, 72% in EBITDA, and 103% in PAT. At the upper band, valuation stands at 29× FY25 PE, considered fair for a growth company.

TruAlt Bioenergy IPO GMP Review – Apply or Not?

Strengths: ₹109 GMP today, oversubscription from retail/HNI, government policy support, anchor backing.
Risks: Valuation slightly stretched, QIB participation moderate.
Verdict: Analysts recommend Subscribe, citing strong listing gains potential and long-term growth in renewable energy.

Other IPOs in Focus

The IPO season is buzzing with:

Jinkushal Industries IPO GMP today – ₹17 premium, 14% gain expected.
Pace Digitek IPO GMP today price – positive premium with good retail demand.
Glottis Limited IPO GMP today – modest grey market traction.
BMW Ventures IPO GMP – upcoming, gaining investor chatter.

TruAlt Bioenergy stands out due to its bioenergy sector focus and strong fundamentals.

FAQs on TruAlt Bioenergy IPO GMP

Q1. What is the IPO of TruAlt Bioenergy?
TruAlt Bioenergy IPO is a ₹839.28 crore public issue (₹750 crore fresh issue + ₹89.28 crore OFS) in the renewable energy and transformer business.

Q2. What is the GMP of TruAlt Bioenergy IPO today?
The TruAlt Bioenergy IPO GMP today is ₹109, indicating an expected listing near ₹605 per share.

Q3. What is the IPO date of TruAlt Bioenergy?
The IPO opened on September 25, 2025 and closed on September 29, 2025. Listing date is October 3, 2025.

Q4. What is the subscription status of TruAlt Bioenergy IPO?
By Day 3, the IPO was subscribed 2.25× overall (Retail 1.64×, NII 5.48×, QIB 0.90×).

Q5. What is the share price target of TruAlt Bioenergy for 2025?
Analysts suggest a TruAlt Bioenergy share price target 2025 of ₹700–₹750, depending on execution and policy support.

Q6. What is IPO GMP in the grey market?
IPO GMP (Grey Market Premium) is the unofficial premium over the IPO price where shares trade before listing. It reflects demand but is not regulated.

Q7. Is GMP good or bad for IPO?
A strong GMP (like ₹109 today) signals demand and potential gains, but it is unofficial and speculative.

Q8. What is running GMP in IPO?
Running GMP is the live premium quoted in the grey market before listing. For TruAlt Bioenergy, it’s ₹109 today.

Q9. Is high GMP always good?
Not always. High GMP may reflect hype. Fundamentals, valuations, and subscription status matter equally.

Q10. Which IPO is best to buy now?
Among current issues, TruAlt Bioenergy IPO and Jinkushal Industries IPO are seeing the strongest retail demand.

Q11. What is the price of Transrail IPO GMP today?
Currently, the market focus is on TruAlt Bioenergy IPO GMP today at ₹109; Transrail GMP updates are awaited.

Q12. TruAlt Bioenergy IPO GMP in Hindi?
आज का TruAlt Bioenergy IPO GMP ₹109 है, जो संकेत देता है कि लिस्टिंग लगभग ₹605 पर हो सकती है।

Q13. TruAlt Bioenergy IPO GMP % today?
At ₹109 GMP over ₹496, the expected listing gain is nearly 22%.

Summary:
The TruAlt Bioenergy IPO GMP today at ₹109 suggests strong listing gains with subscription 2.25× overall. With a listing date of October 3, 2025, and a share price target of ₹700–₹750 for 2025, the IPO has strong fundamentals in the bioenergy space. Analysts recommend Subscribe for both short-term gains and long-term renewable energy growth.

Tags GK Energy IPO, IPO, IPO GMP, Jinkushal Industries IPO, TruAlt Bioenergy, TruAlt Bioenergy IPO, TruAlt Bioenergy IPO GMP Today

Business & Economy Stock Market 🔥 Trending

Jinkushal Industries IPO GMP Today: Grey Market Premium, Details & Review

Post author By John Martin
Post date September 29, 2025

Jinkushal Industries IPO GMP Today ₹17 | Grey Market Premium, Subscription & Review

Jinkushal Industries IPO GMP Today

The grey market premium (GMP) for Jinkushal Industries IPO is currently hovering around ₹17 per share, indicating an expected listing price of about ₹138 against the upper band of ₹121. This suggests a 14–15% listing gain if sentiments hold.

Jinkushal Industries IPO Subscription Status

The IPO has attracted strong demand from retail and non-institutional investors.

Overall Subscription: Over 5× by Day 2
Retail Investors: Oversubscribed multiple times
NII (Non-Institutional): Strong traction
QIBs (Institutional): Relatively weak interest so far

Jinkushal Industries IPO Details

IPO Open Date: 25 September 2025
IPO Close Date: 29 September 2025
Price Band: ₹115 – ₹121 per share
Lot Size: 120 shares
Total Issue Size: ~₹116 crore
Proposed Listing Date: 3 October 2025
Use of Proceeds: Working capital and general corporate purposes

Jinkushal Industries IPO Review

Market experts suggest the IPO is fairly priced with limited room for sharp upside, though retail demand may drive a positive listing. Investors should balance the possibility of moderate listing gains with the company’s long-term fundamentals such as global demand for construction machinery, export growth, and margin pressures.

Jinkushal Industries IPO GMP Share Price

At a GMP of around ₹17, the grey market is factoring a share price of ₹138 on listing day, which is approximately a 14% premium over the IPO issue price.

Jinkushal Industries IPO GMP Price & Review

GMP Price Estimate: ₹138 (₹121 issue price + ₹17 GMP)
Review: GMP suggests healthy but not extraordinary listing gains. Investors looking for short-term profits may find this attractive, while long-term investors should analyze fundamentals before committing.

TruAlt Bioenergy IPO GMP

The TruAlt Bioenergy IPO is also gaining attention in the grey market. Current GMP trends suggest decent premium expectations, though subject to volatility as subscription figures evolve.

Pace Digitek IPO GMP

Pace Digitek IPO grey market trends indicate positive sentiment. Investors are closely tracking subscription numbers before finalizing bids.

Trident IPO GMP Today

The Trident IPO GMP today shows moderate listing premium expectations. While retail interest is strong, actual listing gains will depend on overall subscription strength and market mood.

Advance Agrolife IPO GMP

The Advance Agrolife IPO grey market premium is under watch, with investors betting on short-term listing benefits. However, fundamentals and valuation remain important factors.

Pace Digitek IPO

Beyond GMP, the Pace Digitek IPO details highlight its focus on technology services and a fast-growing digital market. Subscription updates will define listing performance.

TruAlt Bioenergy IPO

The TruAlt Bioenergy IPO offers exposure to India’s renewable energy sector. Early demand trends are encouraging, and grey market buzz points to a premium listing possibility.

Jinkushal Industries IPO GMP & Grey Market

Q1. How much GMP is good for IPO?
A GMP of 15–30% is generally considered healthy for IPO investors, but it is not a guarantee of listing gains.

Q2. What is the issue size of Jinkushal Industries IPO?
The total issue size is approximately ₹116 crore.

Q3. What is IPO GMP grey market?
IPO GMP (Grey Market Premium) is the unofficial premium at which IPO shares trade in the grey market before official listing.

Q4. What is running GMP in IPO?
The running GMP is the current prevailing grey market premium for an IPO, which can fluctuate daily based on demand and sentiment.

Q5. Is high GMP good?
Yes, a high GMP indicates strong market sentiment, but it may not always reflect the company’s true fundamentals.

Q6. Which IPO is best to buy?
The “best IPO” depends on individual risk appetite and investment goals. Investors should look at subscription status, company fundamentals, and valuation—not just GMP.

Q7. Jinkushal Industries IPO GMP Price Today?
The GMP today is around ₹17, implying a listing price near ₹138.

Q8. Jinkushal Industries IPO Subscription Status?
It is already subscribed over 5× overall, with strong demand from retail investors.

Q9. Jinkushal Industries IPO Review?
Experts call it fairly priced, with chances of modest listing gains and potential long-term growth if global expansion sustains.

Q10. TruAlt Bioenergy IPO GMP Today?
The grey market for TruAlt Bioenergy IPO is showing premium trends, reflecting positive listing expectations.

Tags Grey Market Premium, IPO, IPO GMP, Jinkushal Industries, Jinkushal Industries IPO

Business & Economy Opinion & Editorials Politics Stock Market Top Stories US News World News 🔥 Trending

Trump Links Autism to Tylenol and Vaccines — Experts Say Claims Not Backed by Science

Post author By John Martin
Post date September 23, 2025
1 Comment on Trump Links Autism to Tylenol and Vaccines — Experts Say Claims Not Backed by Science

Trump Links Tylenol & Vaccines to Autism — Experts Push Back

Washington, Sept 22, 2025: In a dramatic White House announcement, President Donald Trump warned pregnant women against using Tylenol and raised new doubts about routine childhood vaccines. Standing alongside Health Secretary Robert F. Kennedy Jr., Trump said the popular pain reliever — known generically as acetaminophen (pronounced uh-SEE-tuh-MEE-nuh-fen) — may be linked to autism in children.

But here’s the catch: scientists, doctors, and Tylenol’s maker Kenvue (NYSE: KVUE, a spinoff from Johnson & Johnson, JNJ) say decades of research show no causal link.

What Trump Said about Autism & Tylenol?

“Don’t take Tylenol. Don’t take it,” Trump said, adding that parents should avoid letting doctors “pump your baby up with the largest pile of stuff” when it comes to vaccines.

Trump also pushed splitting the MMR vaccine (measles, mumps, rubella) into three separate shots.
He questioned giving the Hepatitis B vaccine to newborns in the first 24 hours of life.
And, in an unusual twist, he promoted leucovorin (a form of folinic acid, often used in cancer care) as a potential treatment for autism symptoms.

What Science Actually Shows on Tylenol

No proven link: A 2024 Swedish study of 2.5 million children found no causal connection between prenatal acetaminophen use and autism.
Mixed signals: A 2025 review of 46 studies suggested there might be associations, but experts say that does not prove causation.
Medical advice remains the same: Groups like the American College of Obstetricians and Gynecologists still consider acetaminophen the safest pain/fever medicine during pregnancy — when used at the lowest dose, for the shortest time.

Expert Reactions on Trump Tylenol debate

Coalition of Autism Scientists: “The data cited do not support the claim that Tylenol causes autism.”
Kenvue: “We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers and parents.”
UK Health Regulator: Paracetamol (the same drug outside the U.S.) is safe and there is no autism evidence.

Autism researcher Dr. Diana Schendel said the Tylenol–autism question has been studied for years: “Without showing new evidence, these announcements become reckless and potentially harmful.”

Market Impact

Kenvue stock (KVUE) plunged over 7% after Trump’s remarks but recovered 5% in late trading.
Johnson & Johnson (JNJ), the former parent company, also saw minor volatility.
Analysts say the absence of new science means the stock should stabilize, though lawsuits over Tylenol and autism claims could continue.

Why This Matters

Pregnant women are confused: The president’s advice contradicts official medical guidance.
Vaccine fears resurface: Trump and RFK Jr.’s comments revived the long-debunked theory linking vaccines to autism — a claim rejected by decades of global research.
Autism advocacy groups worry the announcement fuels fear while giving false hope about treatments like leucovorin.

Trump’s announcement has once again pushed controversial, unproven medical claims into the spotlight. While Tylenol lawsuits and studies keep the debate alive, the scientific consensus is clear: acetaminophen does not cause autism and vaccines remain safe, saving millions of lives.

👉 Expect the FDA to review Tylenol labels and the debate to continue — but for now, experts urge pregnant women to follow their doctor’s advice, not political speeches.

Read Checkout this post: Tylenol, Autism & Trump: Panic, Stocks, and a New Wave of Questions

Read more at: Todaybeat.com

Tags acetaminophen, Autism, President Donald Trump, Trump, Tylenol, White House announcement

Stock Market Top Stories 🔥 Trending

Investors Rush for GK Energy IPO – GMP Buzzing at 20%! Should You Expect a Jackpot

Post author By John Martin
Post date September 23, 2025

GK Energy IPO GMP Today: Oversubscribed 89×, Grey Market Premium Hints at 13–20% Listing Gains

New Delhi, September 23, 2025: The ₹464 crore GK Energy IPO has closed today and it turned out to be a blockbuster. The issue was subscribed nearly 90 times, which clearly shows how much investors trusted this company. Now all attention is on September 26, when the shares will hit the market.

Quick GK Energy IPO Details

The company had fixed a price band of ₹145 to ₹153 per share. A lot contained 98 shares, which meant retail investors had to invest at least ₹14,994. In total, the issue size was about ₹464.26 crore. The stock will get listed on both NSE and BSE.

Big Subscription Numbers for GK Energy IPO

Institutions (QIBs): 186.29×
HNIs: 122.73×
Retail Investors: 20.79×

It’s not just the big institutions, even small investors rushed in. This mix of retail and institutional demand is what makes this IPO stand out.

Grey Market Premium Buzz for GK Energy IPO

Right now, the Grey Market Premium (GMP) is about ₹20 per share above the issue price. That signals a likely 13% listing gain.

Some reports even claim the GMP touched ₹31, which, if true, means the stock could list with almost 20% upside. In simple terms, the share may open somewhere between ₹173 and ₹184, if this trend continues.

Why Investors Are So Interested in GK Energy IPO

First, the company is part of the renewable energy sector, and that’s one of the hottest themes in India today. Everyone is talking about clean and green energy, and GK Energy fits right in.

Second, the kind of oversubscription we saw tells us that confidence is high. When both retail and big investors chase an IPO, it usually creates a buzz in the market.

And third, many are simply looking for listing gains. GMP has been steady, which gives traders hope for good profits on the first day.

Things You Should Keep in Mind about GK Energy IPO

Of course, GMP is not official. It changes quickly and sometimes doesn’t match the actual listing price. On listing day, a lot of traders may sell immediately, which can make the stock very volatile.

For long-term investors, the real story will depend on how GK Energy performs in terms of profits and how much the government supports renewable projects in the coming years.

How to Buy GK Energy Shares

The IPO has closed, but you can still buy GK Energy shares once they list on September 26, 2025 on NSE and BSE. Here’s how:

Wait for Listing – Shares will start trading on NSE and BSE like any other stock.
Open a Demat + Trading Account – With brokers like Zerodha, Groww, Upstox, ICICI Direct, or HDFC Securities.
Search for GK Energy – On your broker’s app/website, type the stock name or symbol.
Place a Buy Order – Use a market order to buy at current price or a limit to set your price.

⚠️ Note

Listing Day = Volatility. Prices can move up and down fast.
Short-term traders may book profits quickly.
Long-term investors should focus on company growth, not just Day 1 excitement.

Final Word

The GK Energy IPO has already created a storm with heavy oversubscription and a strong grey market buzz. A double-digit listing gain looks possible, but only the market on September 26 will give the final answer.

Whether it opens at 13% or even 20% higher, this IPO has already secured a place as one of the most exciting listings of 2025.